| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
New tests launched in August
New Tests
In August 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in August 2021 by Mayo Clinic Laboratories:
CIFA | Cutaneous Immunofluorescence Antibodies, IgA, Serum
This test is intended for use of confirming a diagnosis of pemphigoid, pemphigus, epidermolysis bullosa acquisita, or bullous lupus erythematosus.
HBAGQ | Hepatitis B Virus Surface Antigen, Quantitative, Serum
This test is intended for use of monitoring of progression of chronic hepatitis B in individuals who are confirmed to be positive for hepatitis B surface antigen, and monitoring of response to antiviral therapy in individuals who have chronic hepatitis B but are negative for hepatitis B e antigen and positive for hepatitis B e antibody.
BIVAL | Bivalirudin, Ecarin, Plasma
This test is intended for monitoring of bivalirudin therapy for patients with prolonged baseline activated partial thromboplastin time.
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:
